What causes prostate cancer?

Written by Zhou Zi Hua

Oncology

Updated on September 22, 2024

00:00

00:00

The current causes of prostate cancer are not completely understood, but a large amount of research indicates that genetic and environmental factors play a significant role. Dietary factors, such as the intake of a large amount of unsaturated fatty acids, vasectomy, smoking, obesity, and alcohol consumption, also increase the risk of developing prostate cancer. Overall, the occurrence and development of prostate cancer are related to various factors, including both internal causes in the patient and the influence of external factors.

Other Voices

home-news-image

Written by Liu Liang

Oncology

32sec

home-news-image

Can people with prostate cancer eat beef?

Patients with prostate cancer can eat beef. Beef is a high-protein food, and as cancer is a consumptive disease, it is generally advised to enhance nutrition in the diet, such as meats, proteins, vegetables, and fruits to maintain a balanced diet with both meat and vegetables. Avoid junk food, such as pickled vegetables from pickled jars, barbecue items, or excessively oily foods with high fat content. Those should be avoided as much as possible, but other foods, including beef, can be consumed.

home-news-image

Written by Zhou Zi Hua

Oncology

1min

home-news-image

Pathological classification of prostate cancer

The classification of precancerous lesions of prostate cancer is divided into two categories: intraductal carcinoma of the prostate and atypical adenomatous hyperplasia. Among these, the relationship between intraductal carcinoma of the prostate and prostate cancer is the closest. Intraductal carcinoma of the prostate is currently recognized as a precancerous lesion of prostate cancer, while atypical adenomatous hyperplasia has not been proven to be a precancerous lesion of prostate cancer according to current evidence. However, the biological behavior of this atypical adenomatous hyperplasia is not very clear yet, so it should be closely monitored. The histological classification of prostate cancer mainly includes the majority of acinar adenocarcinoma and a small amount of ductal adenocarcinoma, with acinar adenocarcinoma being a highly invasive malignant tumor.

home-news-image

Written by Liu Liang

Oncology

36sec

home-news-image

Is prostate cancer sexually transmitted?

Prostate cancer is non-contagious; therefore, it cannot be transmitted through sharing utensils, eating together, or through respiratory pathways. Secondly, prostate cancer is not transmitted through sexual activity; it is non-contagious. In clinical settings, many family members of patients inquire whether malignant tumors are contagious and if they could be infected while caring for the patient. It is important to clarify that malignant tumors are not contagious, and prostate cancer cannot be transmitted through sexual activity.

home-news-image

Written by Liu Liang

Oncology

55sec

home-news-image

Is prostate cancer radiotherapy painful?

Prostate cancer radiotherapy involves high doses of radiation, which typically results in related side effects. However, the severity of these side effects varies from patient to patient depending on individual factors such as their physical constitution. Therefore, clinically, some patients may experience severe symptoms, while others may have milder symptoms, indicating significant individual differences. Common side effects of radiotherapy include radiation cystitis, characterized by frequent urination, urgency, and possibly hematuria. Radiation proctitis is also common, presenting symptoms such as a sensation of heaviness around the anus and diarrhea. Additionally, bone marrow suppression, manifesting as a decrease in white blood cells and platelets, is another side effect.

home-news-image

Written by Zhou Zi Hua

Oncology

51sec

home-news-image

Endocrine therapy after radical prostatectomy for prostate cancer

Endocrine therapy after radical prostatectomy for prostate cancer is equivalent to adjuvant endocrine therapy for prostate cancer. Its purpose is to treat residual lesions, positive residual lymph nodes, and microscopic metastatic foci, thereby improving long-term survival rates. Currently, the indications for adjuvant endocrine therapy are based on postoperative pathology-positive results, positive lymph nodes post-surgery, and postoperative pathology confirmation of stage T3 or T4, but with high-risk factors. According to major guidelines, the duration of adjuvant endocrine therapy should be at least eighteen months.